From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer

• Robert Pirker,
• Martin Filipits

Affiliations

Robert Pirker

Internal Medicine I, Medical University of Vienna, Vienna, Austria

Martin Filipits

Internal Medicine I, Medical University of Vienna, Vienna, Austria